Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Return on Sales (2022 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Return on Sales for 4 consecutive years, with 3.63% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 303.0% to 3.63% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.43% through Dec 2025, down 45.0% year-over-year, with the annual reading at 2.03% for FY2025, 203.0% down from the prior year.
  • Return on Sales hit 3.63% in Q4 2025 for ARS Pharmaceuticals, up from 1.64% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 3.63% in Q4 2025 to a low of 2424.57% in Q3 2023.
  • Historically, Return on Sales has averaged 407.71% across 4 years, with a median of 20.33% in 2022.
  • Biggest five-year swings in Return on Sales: crashed -238949bps in 2023 and later skyrocketed 241405bps in 2024.
  • Year by year, Return on Sales stood at 26.99% in 2022, then tumbled by -1310bps to 380.53% in 2023, then skyrocketed by 100bps to 0.6% in 2024, then soared by 504bps to 3.63% in 2025.
  • Business Quant data shows Return on Sales for SPRY at 3.63% in Q4 2025, 1.64% in Q3 2025, and 3.03% in Q2 2025.